A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Clinical trial NCT06121843 · RECRUITING
Trial details
- NCT number
- NCT06121843
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-22
- Primary completion
- 2028-08-01
- Enrollment
- 187
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.